Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis

Journal of Rheumatology

Volumn 37, Issue 1, 2010, Pages 45-52

  Lee, Hui Ting ^a,b   Shiao, Yu Ming ^b   Wu, Tsai Hung ^a,b   Chen, Wei Sheng ^a,b   Hsu, Yung Hsiang ^c   Tsai, Shih Feng ^b   Tsai, Chang Youh ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Anti dsDNA antibodies; B lymphocyte chemoattractant; CXC chemokine; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CHEMOKINE RECEPTOR CXCR5; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG PULSE THERAPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CORTEX; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIGENS, CD19; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; B-LYMPHOCYTES; CHEMOKINE CXCL13; CYCLOSPORINE; FEMALE; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MICE; MIDDLE AGED; RECEPTORS, CXCR5; T-LYMPHOCYTES; YOUNG ADULT;

EID: 73649136091     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090450     Document Type: Article

References (35)

1. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201:703-11.
2. Jacobi AM, Diamond B. Balancing diversity and tolerance: lessons from patients with systemic lupus erythematosus. J Exp Med 2005;202:341-4.
3. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
4. Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001;12:1369-82.
5. Kulkarni O, Anders HJ. Chemokines in lupus nephritis. Front Biosci 2008;13:3312-20.
6. Rovin BH. The chemokine network in systemic lupus erythematous nephritis. Front Biosci 2008;13:904-2.
7. Hsieh SC, Wu TH, Tsai CY, Li KJ, Lu MC, Wu CH, et al. Abnormal in vitro CXCR2 modulation and defective cationic ion transporter expression on polymorphonuclear neutrophils responsible for hyporesponsiveness to IL-8 stimulation in patients with active systemic lupus erythematosus. Rheumatology 2008;47:150-7.
8. Ishikawa S, Sato T, Abe M, Nagai S, Onai N, Yoneyama H, et al. Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by CD11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med 2001;193:1393-402.
9. Sato T, Ishikawa S, Akadegawa K, Ito T, Yurino H, Kitabatake M, et al. Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur J Immunol 2004;34:3346-58.
10. Ishikawa S, Matsushima K. Aberrant B1 cell trafficking in a murine model for lupus. Front Biosci 2007;12:1790-803.
11. Ito T, Ishikawa S, Sato T, Akadegawa K, Yurino H, Kitabatake M, et al. Defective B1 cell homing to the peritoneal cavity and preferential recruitment of B1 cells in the target organs in a murine model for systemic lupus erythematosus. J Immunol 2004;172:3628-34.
12. Hayakawa K, Hardy RR. Development and function of B-1 cells. Curr Opin Immunol 2000;12:346-53.
13. Hardy RR, Hayakawa K. B cell developmental pathways. Ann Rev Immunol 2001;19:595-621.
14. Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002;20:253-300.
15. Duan B, Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006;5:403-8.
16. Youinou P, Renaudineau Y. The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun Rev 2007;7:149-54.
17. Dauphinee M, Tovar Z, Talal N. B cells expressing CD5 are increased in Sjögren's syndrome. Arthritis Rheum 1988;31:642-7.
18. Le Pottier L, Devauchelle V, Pers JO, Jamin C, Youinou P. The mosaic of B-cell subsets (with special emphasis on primary Sjögren's syndrome). Autoimmun Rev 2007;6:149-54.
19. Mantovani L, Wilder RL, Casali P. Human rheumatoid B-1a (CD5+ B) cells make somatically hypermutated high affinity IgM rheumatoid factors. J Immunol 1993;151:473-88.
20. Ishikawa S, Nagai S, Sato T, Akadegawa K, Yoneyama H, Zhang YY, et al. Increased circulating CD11b+CD11c+ dendritic cells (DC) in aged BWF1 mice which can be matured by TNF-α into BLC/CXCL13-producing DC. Eur J Immunol 2002;32:1881-7.
21. Iizuka J, Katagiri Y, Tada N, Murakami M, Ikeda T, Sato M, et al. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest 1998;78:1523-33.
22. Murakami M, Yoshioka H, Shirai T, Tsubata T, Honjo T. Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. Int Immunol 1995;7:877-82.
23. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
25. Meijer J, Zeelenberg IS, Sipos B, Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res 2006;66:9577-81.
26. Zheng B, Ozen X, Zhang X, De Silva S, Marinova E, Guo L, et al. CXCL13 neutralzation reduces the severity of collagen-induced arthritis. Arthritis Rheum 2005;52:620-6.
27. Li KJ, Lu MC, Hsieh SC, Wu CH, Yu HS, Tsai CY, et al. Release of surface-expressed lactoferrin from polymorphonuclear neutrophils after contact with CD4+ T cells and its modulation on Th1/Th2 cytokine production. J Leukoc Biol 2006;80:350-8.
28. Koutouzov S, Jeronimo AL, Campos H, Amoura Z. Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 2004;30:529-58.
29. Arbuckle MR, James JA, Kohlhase KF, Rubertone MV, Dennis GJ, Harley JB. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001;54:211-9.
30. Tsai CY, Wu TH, Sun KH, Liao TS, Lin WM, Yu CL. Polyclonal IgG anti-dsDNA antibodies exert cytotoxic effect on cultured rat mesangial cells by binding to cell membrane and augmenting apoptosis. Scand J Rheumatol 1993;22:162-71.
31. Luan HY, Tang SJ, Yang W, Tsai CY, Sun GH. Monoclonal anti-double stranded DNA antibodies cross-react with phosphoglycerate kinase 1 and inhibit the expression and production of IL-2 in activated Jurkat T cell line. Clin Immunol 2006;120:326-34.
32. Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis - the emerging mechanisms. Autoimmun Rev 2008;7:317-21.
33. Vielhauer V, Anders HJ, Schlöndorff D. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Semin Nephrol 2007;27:81-97.
34. Vielhauer V, Anders HJ. Blockade of chemokine-mediated tissue injury in lupus nephritis. Endocr Metab Immune Disord Drug Targets 2006;6:313-21.
35. Hasegawa H. Chemokine blockade for lupus model mice. Front Biosci 2008;13:2900-8.